Kodiak Sciences Inc.

NasdaqGM:KOD Stock Report

Market Cap: US$325.0m

Kodiak Sciences Balance Sheet Health

Financial Health criteria checks 6/6

Kodiak Sciences has a total shareholder equity of $185.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $372.7M and $187.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$197.86m
EquityUS$185.37m
Total liabilitiesUS$187.30m
Total assetsUS$372.67m

Recent financial health updates

Recent updates

Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)

Nov 15

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Aug 02
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Apr 17
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Dec 29
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Sep 09
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

May 26
Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Jan 04
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Sep 25
Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

GreenWood Investors - Kodiak Sciences: The Busted Biotech World

Aug 25

Kodiak Sciences FQ1 2022 Earnings Preview

Aug 07

Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

May 18
Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?

Kodiak Sciences: Potential For Comeback After Trial Setback

May 17

Kodiak Sciences: KSI-301 Disappoints

Feb 25

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter

Feb 15

We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Oct 11
Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation

Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company

Jul 19

Kodiak Sciences EPS in-line

May 10

Kodiak Sciences hits the capital raise button; shares dip after hours

Nov 16

Kodiak Sciences EPS misses by $0.12

Nov 09

Financial Position Analysis

Short Term Liabilities: KOD's short term assets ($202.5M) exceed its short term liabilities ($24.1M).

Long Term Liabilities: KOD's short term assets ($202.5M) exceed its long term liabilities ($163.2M).


Debt to Equity History and Analysis

Debt Level: KOD is debt free.

Reducing Debt: KOD had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KOD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KOD has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 26.5% each year.


Discover healthy companies